Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Management of variant acute promyelocytic leukemia

Jie Jin • 1 Jun 2021
EHA 2021
Anemias Myelofibrosis Myeloproliferative Neoplasms Jaktinib

Jie Jin, MD, PhD, Zhejiang Medical University, Hangzhou, China, outlines the use of jaktinib commenting on the mechanism of action and its rationale for use in the treatment of myelofibrosis. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Jie Jin

0:48
ZGJAK002: jaktinib shows efficacy in myelofibrosis
Jie Jin • 1 Jun 2021
1:08
QoL benefits of jaktinib for myelofibrosis patients
Jie Jin • 1 Jun 2021

Related Videos

0:52
The unmet needs that remain for patients with systemic mastocytosis
Deepti Radia • 29 Apr 2024
2:13
Current and emerging treatment options for patients with MF who are ineligible for ruxolitinib
Claire Harrison • 29 Apr 2024
1:40
The current therapeutic landscape for indolent and advanced systemic mastocytosis
Deepti Radia • 29 Apr 2024
2:12
The current challenges and unmet needs in myelofibrosis: clinical practice and trials
Claire Harrison • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals